UM

Browse/Search Results:  1-1 of 1 Help

Selected(0)Clear Items/Page:    Sort:
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy Journal article
Lu, Dan, Xu, Zepeng, Zhang, Ding, Jiang, Min, Liu, Kefang, He, Juanhua, Ma, Dongli, Ma, Xiaopeng, Tan, Shuguang, Gao, George F., Chai, Yan. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy[J]. Frontiers in Immunology, 2022, 13, 826045.
Authors:  Lu, Dan;  Xu, Zepeng;  Zhang, Ding;  Jiang, Min;  Liu, Kefang; et al.
Favorite | TC[WOS]:22 TC[Scopus]:24  IF:5.7/6.8 | Submit date:2022/04/06
Antibody  Cemiplimab  Immune Checkpoint Therapy (Ict)  N58 Glycosylation  Pd-1